There are no projects in the garbage can.
The CART_Andalucía project is moving into Phase 2, a key stage focused on the scientific development of the CAR-T therapy prototype and the conduct of exploratory preclinical trials to assess its safety, efficacy and manufacturability.
This phase involves the two successful bidders selected in Phase 1, who continue to lead the project’s technological development: the GRANA CAR-T joint venture, comprising LentiStem Biotech, S.L., CIMA University of Navarra and the University of Navarra Clinic; and the BBZS joint venture, comprising Biotechnology Assets, S.A., the BIOGipuzkoa Health Research Institute, Zera Intein Protein Solutions, S.L. and Science & Innovation Link Office, S.L.
Development of the CAR-T prototype
During this stage, the necessary research activities are carried out to develop the CAR-T prototype from a scientific and technological perspective. The work includes molecular biology tests aimed at obtaining and evaluating different chimeric antigen receptor (CAR) construct and vector candidates, as well as cell biology assays designed to ensure their correct integration and expression in T cells.
These activities enable the biological behaviour of the various candidates to be analysed and progress to be made in selecting the most suitable design for subsequent preclinical evaluation.
Exploratory preclinical studies
Phase 2 involves conducting exploratory preclinical studies, both in vitro and in a relevant animal model, with the aim of initially characterising the safety, efficacy and biological properties of the CAR-T prototype developed.
These studies provide critical information for understanding the functional profile of the therapy, identifying potential risks and assessing its therapeutic potential prior to progression to regulated phases of development.
What is LentiStem Biotech?
LetiStem is a technology-based company founded by researchers from GENYO, specialising in the development of CAR-T cell-based treatments for solid tumours. Its mission is to develop and produce more effective and safer lentiviral vectors for use in basic research and gene therapy.
See more news
